Related Experiment Videos
Effect of interferon-beta-1b on cognitive functions in multiple sclerosis
1Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel. mdybarak@netvision.net.il
European Neurology
|January 23, 2002
Summary
Interferon-beta-1b treatment improved cognitive functions like attention and memory in relapsing-remitting multiple sclerosis (MS) patients. This suggests immunomodulatory drugs can prevent cognitive decline in MS.
Area of Science:
- Neuroscience
- Immunology
- Clinical Medicine
Background:
- Multiple sclerosis (MS) is a central nervous system disease affecting cognition in 45-65% of patients, significantly impacting quality of life.
- Cognitive dysfunction is a prevalent and debilitating symptom in multiple sclerosis (MS).
Purpose of the Study:
- To evaluate the impact of 1-year interferon-beta-1b (IFNbeta-1b) treatment on cognitive functions in relapsing-remitting MS patients.
- Assessing the efficacy of immunomodulatory therapy in mitigating cognitive decline associated with MS.
Main Methods:
- Cognitive functions including verbal learning, recall, attention, concentration, and fluency were assessed using a test battery.
- A cohort of relapsing-remitting MS patients receiving IFNbeta-1b was compared to a control group matched for neurological disability.
Main Results:
- IFNbeta-1b treatment led to significant improvements in complex attention, concentration, and visual learning/recall (p < 0.05).
- The control group showed significant deterioration in complex attention, verbal fluency, and visual learning/recall (p < 0.05).
- No cognitive deterioration was observed in other measured domains for the IFNbeta-1b treated group.
Conclusions:
- Immunomodulatory drugs like IFNbeta-1b can inhibit cognitive deterioration in MS patients.
- Reducing relapse rates and slowing disease progression with these therapies may preserve cognitive function.